ImmunityBio completes database lock for QUILT-2.005 trial; topline results expected November 2026

ImmunityBio completed the database lock for Cohort A of its QUILT-2.005 registrational trial evaluating Anktiva plus BCG versus BCG alone in BCG-naive NMIBC patients. The company anticipates reporting topline results in November 2026 and remains on track to submit an sBLA to the FDA in Q4 2026.

Detected & updated continuously · Source: Nebula